Trial Profile

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary)
Indications Bladder cancer; Carcinoma
Focus Adverse reactions
Sponsors TARIS Biomedical

Most Recent Events

10 Jan 2020 Status changed from active, no longer recruiting to completed.
22 Aug 2019 Planned End Date changed from 1 Apr 2018 to 1 Oct 2019.
26 Jun 2019 Results (positive safety, tolerability and preliminary efficacy data from the full patient cohort (n=20)) presented in a TARIS Biomedical media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com